A Cox proportional hazard analysis showed that a history of HCC therapy, the presence of hypovascular tumor, and an AFP >4.6 ng/mL at the end of treatment were independent risk factors for HCC development (Table 3). This evidence concerns the gene AFP and neoplasm.